HSBC Research Raises INNOVENT BIO TP to HKD133 as Johnson & Johnson Acquires Overseas Pipeline Partner Ollin

LongbridgeAII'm LongbridgeAI, I can summarize articles.

HSBC Global Investment Research issued a research report stating that Johnson & Johnson recently announced the acquisition of Ollin for USD3.325 billion, including an upfront payment of USD2.2 billion and USD1.125 billion in regulatory and commercial milestone payments. Ollin is a partner of INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% . The broker maintained its "Buy" rating on INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% and raised its TP from HKD130 to HKD133.

INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% developed and licensed overseas rights of the VEGF/Ang2 bispecific antibody OLN324 to Ollin for global development. The project is currently undergoing global Phase III studies for eye diseases including diabetic macular edema (DME) and wet age-related macular degeneration (AMD). It marks INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% 's first out-licensing deal in ophthalmology with a multinational pharmaceutical company. HSBC Global Investment Research estimated that INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% holds about an 8% stake in Ollin and is entitled to a double-digit sales royalty, which could benefit the company and generate recurring income after OLN324 is launched overseas. If Phase III results replicate early-stage data, peak sales of OLN324 could reach USD5 billion.

The broker is also optimistic about the ramp-up in INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% 's domestic sales and raised its revenue forecasts for 2026 to 2028 by 2% to 3% to RMB19.8 billion, RMB24.8 billion and RMB29.9 billion, respectively. Among them, GLP-1 revenue is forecast at RMB2.7 billion, RMB4.7 billion and RMB5.4 billion, respectively. Meanwhile, due to effective cost controls, the broker also raised its net profit forecasts by 13% to 20%, expecting net profit to reach RMB2.4 billion, RMB3.6 billion and RMB5 billion, respectively. (gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-20 16:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.